INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10523268		
Filing Date		2005-07-07		
First Named Inventor John		Schenk		
Art Unit		1632		
Examiner Name Marci		a Stephens Noble		
Attorney Docket Number		XY-Low Pressure USNP		

				U.S.	PATENTS		Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant Appear	
	1	US501749	A	1991-05-21	Grooth et al.			
	2	5934885		1999-08-10	Farrell et al.			
	3	7195920		2007-03-27	Seidel et al.			
	4	5559032		1996-09-24	Pomeroy et al.			
	5	3756459		1973-09-04	Bannister			
If you wis	h to a	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant Appear	
	1	20050064383	A1	2005-03-24	Bashkin et al.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10523268		
Filing Date			2005-07-07		
First Named Inventor John		John	Schenk		
Art Unit			1632		
Examiner Name Marci		Marci	a Stephens Noble		
	Attack on Dealest Mount	nr.	VV Law Processo LICND		

	2	20060281176	A1	2006-12	-14	Seidel et al.					
	3	20070026378	A1	2007-02	-01	Schenk					
	4	20070026379	A1	2007-02	-01	Seidel et al					
	5	20060118167	A1	2006-06	-08	Neas et al.					
	6	20050011582	A1	2005-01	-20	Haug					
If you wis	h to a	dd additional U.S. Publi									
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	or v		or Relevant	
	1	2003020877	wo		A2	2002-08-15	Pharmacia Corp. (c Monsanto Compan				
	2	2007/016090	wo		A2	2007-02-08	XY, Inc.				
	3	2007/016090	WO		A2	2007-02-08 1985-05-08	XY, Inc. Technicon Insrume Corp.	nts			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number Filing Date First Named Inventor John S		10523268	
			2005-07-07	
			Schenk	
	Art Unit		1632	
			a Stephens Noble	
			XY-Low Pressure USNP	

	5	2002041906	wo	A2	2001-11-21	Pharmacia Corp. (c/o Monsanto Company)				
	6	2006060770	wo	A2	2006-08-06	XY, Inc.				
If you wisl	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add button	Add			
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove			
Examiner Initials* Cite (note name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, dity and/or country where published.										
	1	Hanania, E. G. et al. A novel Automatical Method of Scanning Cytometry and Laser-Induced Necross Applied to Tumor Cell Purging, Blood: 15 November 1959, Vol. 94, No. 10, suppl 1 part 1								
	2	Purdy, P. H. et al., Effect of Adding Cholesferol to Bull Sperm Membranes on Sperm Capacitation, the Acrosome Reaction, and Fertility, Biology of Reproduction 71, 522-527 (2004)								
	3	Purdy, P. H. et al., Effect 36-45	t of cholesterol-los	ided cyc	lodextrin on the	cryosurvival of bull sperm, (Cryobiology 48 (2004)			
	Moce E., et al., Cholesterol-loaded cyclodexfrins acced to fresh bull ejaculates improve sperm cryosurvival, J. Anim. 4 Sci., 2006, 84,826-833									
	5	Erath, B. A., et al. Integration of Early Wearing and Scored Semen into a Single-Calf Holfer System to Increase Value of Non-Registerment Heilers, Proceedings, Western Section, American Society of Astimal Science, Vol. 51,441-443, June 2000								
	6	Ereth, B.A., et al. Integration of Early Weaning and Sexed Semen into a Single-Call Helfor System to increase Value of Non-Replacement Hefters, Abstract Only, Journal of Ansmall Science, Vol. 78, Supplement 2, 2000								
	7		Bavister, B.D. et al., The effects of Sperm Extracts and Energy Sources on the Motility and Acromosome Reaction of harmster Spermatozoa in vitero, Biology of Reponduction 16, 228-237 (1997)							

8	Fattouh, ELS M. et al., Effect of Catfline on the Post-Thaw Motility of Buffalo Spermatozoa; Therogenology, July 1991, vol. 36 No. 1	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered Date Consid

See Kinz Codes of USPTO Potent Documents at sure: USETO.QQL/or sNEEP 901.04. * Enter of this tissued the document, by the broadest rock (NIPO) Sharked 37.3. * "Enter of this patient per seed to comment, the or document or the year of the register result process to seed on the period the patient document. The ordinary process to seed on the period the period the period process to seed on the period of the

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

			10523268	
			2005-07-07	
			Schenk	
	Art Unit		1632	
	Examiner Name Marcia		a Stephens Noble	
	Attorney Docket Number		XY-Low Pressure USNP	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.98 to make the	appropriate selection(s):
---------------	--------------	------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- | Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

on the agriculture.								
Signature	/Nicole A. Ressue/	Date (YYYY-MM-DD)	2007-03-29					
Name/Print	Nicole A. Ressue	Registration Number	48665					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.